November 02, 2022

On October 31, 2022, the U.S. Food and Drug Administration recommended that healthcare providers discuss alternative options for magnetic resonance imaging–guided breast biopsy procedures with patients if a facility is unable to perform it because of a shortage of Philips Invivo MRI breast biopsy grid plates and other Philips Invivo MRI disposables. 

November 02, 2022

Anthony Fauci, MD, reflected on his career in government and gave insight into what he’s doing next in a statement released in August 2022 addressing his departure from his positions as director of the National Institute of Allergy and Infectious Diseases (NIAID), chief of the NIAID Laboratory of Immunoregulation, and chief medical advisor to President Joe Biden. Fauci served as NIAID director for 38 years and held a career spanning more than 50 years in government service.

November 01, 2022

Many of our patients are individuals who haven’t developed cancer but might have a concerning family history of the disease. We rely on healthcare providers like oncology nurses to identify individuals with concerning cancer histories and refer them to genetic counselors for a complete risk assessment, including genetic testing when appropriate, to determine their risk and recommend proactive measures to reduce it.

October 27, 2022

More than an activity for children, many people find that the cathartic art of coloring, particularly intricate patterns and swirling mandalas, may help them destress. The first adult coloring book was published in the 1960s, but adults began embracing the idea en mass in April 2015 when illustrator Johanna Basford was featured on NPR’s All Things Considered. By the end of that year, 12 million adult coloring books were sold in the United States.

October 26, 2022

On October 25, 2022, the U.S. Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli®), the first bispecific B-cell maturation antigen–directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.